链球菌噬菌体裂解酶在大肠杆菌中的表达、纯化及活性检测

噬菌体裂解酶是噬菌体产生的细胞壁水解酶,通过水解宿主菌细胞壁使子代噬菌体释放,在体外能高效且特异性地杀死细菌。本研究旨在克隆和表达链球菌噬菌体裂解酶PlyC,并测定其生物学活性。利用PCR方法扩增PlyC的2条肽链PlyCA和PlyCB,构建表达载体pET-32a(+)-PlyCA和pET-32a(+)-PlyCB,分别转化至大肠杆菌BL21(DE3)中,以0.7 mmol/L IPTG在30 oC诱导7 h实现了高效表达,SDS-PAGE分析表明PlyCA和PlyCB表达量均可达菌体总蛋白的30%以上。采用Ni2+-NTA亲和层析法纯化目的蛋白,其纯度大于95%。用透析复性方法得到目的产物重组链球菌噬菌体裂解酶PlyC,以浊度法和平板计数法检测其体外抗菌效果,扫描电子显微镜观察裂解酶作用前后细菌细胞形态变化。结果表明重组PlyC能特异性裂解化脓性链球菌(A组β-溶血性链球菌),以4μg/mL浓度作用于OD600为0.56的菌液60 min后杀菌率达99.6%,扫描电镜观察结果显示该酶作用于菌体后,链球菌细胞裂解,呈碎片状态。本研究为开发一种新型、高效的链球菌感染疾病治疗药物打下了基础。     

肺炎链球菌SpxA蛋白的原核表达、纯化及多克隆抗体的制备

目的 构建肺炎链球菌SpxA蛋白的原核表达系统,制备其多克隆抗体.方法 设计引物,利用PCR技术扩增肺炎链球菌D39菌株的spxA基因,并插入表达载体pET-28a（＋）内,测序鉴定.重组质粒转化至大肠埃希菌BL21（DE3）中,以IPTG诱导表达含6个组氨酸标签的SpxA重组蛋白,经Ni-NTA亲和层析柱纯化后,以其为抗原免疫BALB/c小鼠制备多克隆抗体.用ELISA及Western印迹方法分别检测多克隆抗体的效价及特异性.结果 从大肠埃希菌中诱导出高表达的SpxA重组蛋白,纯化后免疫小鼠获得抗血清,ELISA测定其效价可达1：2 560 000以上,Western印迹结果显示其能特异性地作用于肺炎链球菌SpxA.结论 成功构建了pET-28a（＋）-spxA原核表达质粒,获得了高纯度的目的 蛋白和高滴度、高特异性的多克隆抗体.     

乙肝病毒前S1抗原突变体在大肠杆菌中的可溶性表达及鉴定

乙肝病毒前S1抗原含多个免疫优势表位及乙肝病毒肝细胞受体结合位点,具有重要的生物学功能。为使其高效、可溶性表达,在DnaStar软件辅助分析下,将前S1基因5′端复杂二级结构突变后,克隆入原核表达载体pQE-30a,转化大肠杆菌M15感受态细胞,经IPTG诱导后,获得了高水平、可溶性表达;并对其进行了纯化和鉴定,为进一步研究乙肝病毒前S1抗原的结构功能特点奠定了基础。     

肺炎链球菌假想蛋白SPD0873的表达纯化及保守性分析

目的通过构建原核表达载体,获得纯化的肺炎链球菌S．pn重组假想蛋白SPD0873,并制备多克隆抗体,进一步分析其在常见S．pn菌株中的保守性。方法分离培养D39型肺炎链球菌,获取其基因组DNA。利用PCR方法扩增去除信号肽的spd0873序列,采用基因体外重组法将spd0873序列克隆到原核表达载体pET-32（a）内,测序鉴定。将重组质粒转化到E．coli Rossetta（DE3）中,经IPTG诱导大量表达融合6个组氨酸标签的SPD0873重组蛋白,经Ni—NTA树脂纯化后,获得的重组蛋白用SDS—PAGE和Western印迹鉴定;将鉴定后纯化的蛋白免疫BALB／C小鼠制备多克隆抗体,并用间接ELISA检测多克隆抗体的效价,Western印迹方法分析多克隆抗体的特异性,同时,鉴定该蛋白在5种常见肺炎链球菌分离株的保守性。结果克隆的spd0873序列与GenBank中的数据相符,并实现了SPD0873蛋白高水平的可溶表达。纯化蛋白免疫BALB／C小鼠获得高滴度、高特异性的的多克隆抗体,Western印迹验证SPD0873蛋白在5株常见肺炎链球菌菌株中均有表达。结论成功制备了高滴度、高特异性的SPD0873蛋白多克隆抗体,同时,检测到SPD0873蛋白在5种常见的肺炎链球菌菌株中非常保守,为研究该蛋白的生物学功能及肺炎链球菌多肽联合疫苗的研制奠定了基础。     

融合蛋白GST-Ulp1p在大肠杆菌中的高效可溶性表达及其活性鉴定

利用基因工程技术,体外重组小分子类泛素修饰蛋白酶1(Ulp1)的活性片段,获得高表达、高特异性重组蛋白酶。从酿酒酵母Saccharomyces cerevisia中提取Ulp1编码第403到621个氨基酸残基之间的DNA片段(Ulp1p),在其C端加入6×His并连接到大肠杆菌表达载体pGEX中,构建重组表达质粒pGEX-Ulp1p-his6。将重组质粒转化至大肠杆菌Rosetta(DE3)中,氨苄青霉素抗性筛选转化子。表达、纯化后,以SUMO融合蛋白检测其活性。经过优化,该蛋白可溶性表达,表达量占菌体总蛋白的40.12%。可通过谷胱甘肽琼脂糖凝胶柱或Ni-NTA凝胶亲和层析纯化得到纯度98%的蛋白。经酶切分析,比活力为1.375×104U/mg。融合蛋白GST-Ulp1p-His6无需切除谷胱甘肽S-转移酶(GST)标签,具有很高的活性,制备简易;6×His标签,有利于底物蛋白切割后纯化,减少蛋白损失。本研究为制备高活力的SUMO蛋白酶提供了一个新方法。     

小鼠卵ZP3蛋白的可溶性表达、纯化及免疫活性鉴定

哺乳动物卵透明带3(Zona pellucida 3,ZP3)在诱导获能精子发生顶体反应中发挥着重要作用,其在大肠杆菌中主要以包涵体形式表达。本研究在大肠杆菌中诱导表达可溶性的mZP3融合蛋白,并鉴定该蛋白的免疫活性。将小鼠卵透明带3克隆至pMAL-p2x质粒,转化至大肠杆菌BL21表达菌中。用不同温度、不同IPTG浓度、不同诱导时间及不同浓度的添加剂诱导目的蛋白表达,以筛选出mZP3融合蛋白可溶性表达的最佳条件。大量表达纯化后以Western blotting和ELISA检测蛋白的免疫活性。酶切鉴定及DNA测序表明mZP3已克隆入pMAL-p2x质粒。经优化诱导表达条件,筛选出mZP3融合蛋白可溶性表达的最佳条件为:当A600为0.6时添加0.02 mol/L葡萄糖,以0.6 mmol/L IPTG于25oC条件下诱导表达4 h。ELISA及Western blotting检测结果表明诱导表达的蛋白具有免疫活性。在大肠杆菌中表达并纯化获得可溶性mZP3蛋白,为mZP3免疫不育疫苗研制及其免疫效果检测提供了可溶性抗原。     

肺炎克雷伯菌调控蛋白RcsAB的构建表达及活性鉴定

为了探讨转录调控子Rcs AB对靶基因的转录调控作用,构建肺炎克雷伯菌RcsA和RcsB的重组质粒,之后诱导蛋白表达,提取纯化后测定其活性。PCR得到rcsA、rcsB片段,分别将两DNA片段克隆至表达载体pMAL-C5X、pET28a,构建重组质粒。再将重组质粒导入E. coli BL21(DE3)菌株中,经IPTG诱导后收集菌体,超声破碎。破碎后的上清过柱、透析纯化,得到高纯度的蛋白,通过EMSA进行蛋白活性鉴定。RcsA,RcsB蛋白成功表达纯化,并能够与靶基因结合,初步证明蛋白具有生物学活性。成功制备有生物学活性的RcsA、RcsB蛋白,为进一步研究RcsAB蛋白复合物特异的生物学功能提供物质基础。     

儿童感染肺炎链球菌的青霉素结合蛋白基因突变分析

目的 分析儿童感染肺炎链球菌的青霉素结合蛋白基因突变与青霉素耐药水平之间的关系。方法 自2012年1月至2014年12月期间分离的1 317株肺炎链球菌中随机抽取出青霉素MIC=2.0 µg/mL、4.0 µg/mL、≥8.0 µg/mL各20株共60株作为实验菌株,采用PCR方法对实验菌株进行青霉素结合蛋白PBP1a、PBP1b、PBP2a、PBP2b、PBP2x、PBP3的基因扩增,扩增产物进一步纯化和测序,测序结果与青霉素敏感肺炎链球菌R6就国际上公认的PBPs保守序列进行比对分析。结果 60株肺炎链球菌的PBP2b、PBP1a、PBP2x、PBP2a基因的保守区或保守区附件均发现氨基酸突变,未发现PBP3与PBP1b突变。中介与耐药菌株基因突变位点存在重合,主要出现在单一的PBP1a序列的370STMK模体元件内Thr371Ser置换突变或伴有PBP2b序列的Thr451Ala/Ser和Ala624Gly置换突变,同时PBP2a序列的465SLN模体元件前置位发生Ser461Ala的置换突变。结论 肺炎链球菌对青霉素中、高水平耐药菌株绝大部分合并有不同PBP序列中4~6个氨基酸的置换突变,但合并多个氨基酸置换突变并非必然引起耐药水平相应升高。中、高水平耐药与PBP1a、PBP2b、PBP2a的变异关系密切,其中PBP1a的STMK保守区域Thr371Ser置换是引起耐药的主要因素之一。     

sIL-16在大肠杆菌中的表达及活性分析

用PCR法扩增本室保存的sIL-16cDNA片段,插入含T7启动子的表达载体pET28a( )中构建重组质粒pET-sIL16,转化大肠杆菌BL21(DE3),低温经IPTG诱导蛋白表达,过Ni^2 螯和层析柱一步纯化表达蛋白,重组蛋白与Jurkat细胞共同孵育后,观察它对细胞表面IL-2R表达的影响,结果发现IPTG诱导蛋白表达后,经SDS-PAGE电沪,可以看到在18kD左右出现明显蛋白表达条带,表达量占菌体可溶蛋白的40％左右,纯化蛋白的纯度达90％以上,经重组蛋白处理过的Jurkat细胞表面IL-2R的表达水平比未经它处理的细胞增高了18.54％。     

新型载体蛋白P64K在大肠杆菌中的可溶性表达与纯化

用常规PCR方法从脑膜炎球菌中克隆出P64K基因,构建重组质粒pET28a-P64K转化BL21(DE3)宿主菌,经眦诱导表达筛选P64K蛋白的高表达菌株。结果证实P64K蛋白为胞内可溶性表达,表达量约占胞内总蛋白的30％。重组P64K蛋白经Butyl疏水柱、G200分子筛柱和Q阴离子柱三步层析后纯度达到95％以上,为今后进一步的功能和应用研究打下了良好的基础。     

L——天门冬酰胺酶的可溶性表达研究

来源于大肠杆菌的Ｌ－天门冬酰胺酶是临床化疗的常用药,其毒副作用影响了其更为广泛的临床应用。利用蛋白质工程技术对其进行体外分子改造,获得副作用较小的突变体是克服其毒作用的有效途径。为此,克隆了Ｌ－天门冬酰胺酰的前导信号肽,成熟肽编码序列,以及其释译、转录终止序列,置于一设计合成的中等强度β内酰胺酶启动子调控之下,在大肠杆菌中获得可溶性表达;表达产物可分泌至细菌周质中,并具有催化Ｌ－天门冬酰胺解离为天     

豆豉纤溶酶基因在大肠杆菌中的可溶性表达及纯化(英文)

豆豉纤溶酶是从豆豉中发现的新型纤溶酶.从枯草杆菌DC-12中提取总DNA,PCR法扩增pro-DFE基因.将pro-DFE基因插入载体pET-32a,构建表达质粒pET-pro-DFE,转化大肠杆菌BL21(DE3),对重组菌株进行变温诱导表达,重组菌株于37℃培养至OD600为0.6时,加入终浓度为0.4mmol/L的IPTG于24℃进行诱导,SDS-PAGE显示可溶性重组融合蛋白约占重组蛋白的60%.且少量融合重组蛋白发生自切割,形成成熟的豆豉纤溶酶,破菌上清中含有成熟的豆豉溶栓酶,纤溶活性为200IU/mL.重组酶经纯化后比酶活为1280IU/mg.     

肺炎链球菌pbp2b和pbp1a基因突变与青霉素耐药的相关性研究

目的探讨耐青霉素肺炎链球菌pbp2b和pbp1 a基因的突变与青霉素耐药的关系,为明了肺炎链球菌的耐药性变异机制,防治其感染提供实验依据。方法从呼吸道感染患儿痰标本中分离肺炎链球菌163株,液体培养基连续稀释法测定其对青霉素的最小抑菌浓度(M IC),套式聚合酶链反应(nPCR)扩增pbp2b和pbp1 a基因,扩增产物直接DNA测序,所测序列与青霉素敏感株(SPN R6)的基因序列进行比较,并分析其氨基酸结构的改变。结果 163株肺炎链球菌中检出青霉素敏感菌75株,中度敏感17株,青霉素耐药菌71株(44%)。耐药菌中58株存在pbp2b突变(81.7%),其中,56株为点突变,2株为CCT插入突变;在27株有pbp2b基因突变的B型和C型耐药菌中,21株出现了不同程度的pbp1 a基因突变。PBP2B氨基酸结构改变以苏氨酸变为丙氨酸、精氨酸变为赖氨酸为主,PBP1A以丙氨酸变为苏氨酸、谷氨酸变为天门冬氨酸为主。结论肺炎链球菌的pbp2b和pbp1 a基因突变与对青霉素的耐药性密切相关,PBP2b突变导致低水平耐药;PBP2b和PBP1A突变导致高水平耐药。     

Recombinant production of active Streptococcus pneumoniae CysE in E. coli facilitated by codon optimized BL21(DE3)-RIL and detergent

Abstract

The emergence of drug resistance in Streptococcus pneumoniae (Spn) is a global health threat and necessitates discovery of novel therapeutics. The serine acetyltransferase (also known as CysE) is an enzyme of cysteine biosynthesis pathway and is reported to be essential for the survival of several pathogenic bacteria. Therefore, it appears to be a very attractive target for structure–function understanding and inhibitor design. This study describes the molecular cloning of cysE from Spn in the pET21c vector and efforts carried out for expression and purification of active recombinant CysE. Significant expression of recombinant Spn cysE could be achieved in codon optimized BL21(DE3)-RIL strain as opposed to conventional BL21(DE3) strain. Analysis of codon adaptation index (CAI) with levels of eukaryotic genes and prokaryotic cysEs expressed in heterologous E. coli host suggests that codon optimized E. coli BL21(DE3)-RIL may be a better host for expressing genes with low CAI. Here, an efficient protocol has been developed for recovery of recombinant Spn CysE in soluble and biologically active form by the usage of nonionic detergent Triton X-100 at a concentration as low as 1%. Altogether, this study reports a simple strategy for producing functionally active Spn CysE in E. coli.     

Soluble expression and purification of the functional interleukin-30 protein in Escherichia coli

Interleukin-30 (IL-30), or IL-27p28, is the α subunit of IL-27 constructed by Epstein–Barr virus-induced gene 3 (EBI3) and IL-27p28 binding via noncovalent bonds. IL-30 can be independently secreted and function independently of IL-27. Recent studies demonstrated IL-30 could concurrently antagonize T helper 1 (Th1) and Th17 responses and might have therapeutic implications for controlling autoimmune diseases. However, no reports have stated an efficient method to generate a relatively large quantity of IL-30. In this study, an Escherichia coli expression system for the rapid expression of the mouse IL-30 is developed. For the first time, IL-30 was expressed in a form of soluble fusion protein and purified using a method of simple affinity chromatography. In order to avoid the impact of minor codons on expressing eukaryotic protein in E. coli and to improve the expression quantity, the nucleotide sequence of IL-30 was optimized. The optimized gene sequence was then subcloned into the pET-44a(+) vector, which allowed expression of IL-30 with a fusion tag, NusA. The vector was transformed into E. coli and the expressed fusion protein, NusA-IL-30, was purified by Ni chromatography. Then the fusion tag was removed by cleavage with thrombin. The purity of purified IL-30 was identified using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as well as high-performance liquid chromatography (HPLC) and the purity was up to about 92%. The yield of IL-30 was 8.95 mg from 1 L of bacterial culture. Western blot confirmed the identity of the purified protein. The recombinant IL-30 showed its biological activity by inhibiting Th17 differentiating from naive CD4⁺ T cells. Therefore, this method of express and purifying IL-30 provides novel procedures to facilitate structural and functions studies of IL-30.     

克雷伯氏菌甘油脱水酶基因在大肠杆菌中的克隆与表达

利用PCR技术从克雷伯氏菌(Klebsiella pneumoniae ATCC49790)总DNA中扩增得到甘油脱水酶(glycerol dehydratase,DHAB)基因的DNA片段,并将其连接到表达质粒pSE380,携带有重组质粒pSE-dhaB的大肠杆菌JM109实现了dhaB基因的表达;对含有dhaB工程菌进行表达研究,表明工程菌在37℃,以1．0mmol／L IPTG诱导5h酶活力即达到1164．14u／L,比野生菌酶活力(168．69U／L)提高了6．9倍。     

Antimicrobial activity of sodium citrate against Streptococcus pneumoniae and several oral bacteria

Aims: The aim of this study is to assess the antibacterial activity of sodium citrate against Streptococcus pneumoniae and several oral bacteria. Methods and Results: The antibacterial activity was determined by broth microdilution method. The results showed that although Enterocuccus faecium OB7084 and Klebsiella pneumoniae OB7088 had high tolerance to sodium citrate, several oral bacteria including Fusobacterium nucleatum JCM8532^T, Streptococcus mutans JCM5705^T and Strep. pneumoniae NBRC102642^T were susceptible. Furthermore, the bactericidal activity of sodium citrate against Strep. pneumoniae NBRC102642^T was not influenced by pH in the range of 5·0–8·0, whereas that of sodium lactate was weakened at neutral or weak alkaline pH. When Strep. pneumoniae NBRC102642^T was treated with sodium citrate for 2 h, many burst cells were observed. However, addition of MgCl₂ or CaCl₂ to an assay medium weakened the antimicrobial activity although ZnCl₂ or MnCl₂ did not influence. Conclusions: Independent of pH, sodium citrate inhibited the growth of oral bacteria, which suggests that the mechanism is different from that of sodium lactate. Significance and Impact of the Study: The results presented in this study would be available for understanding the antimicrobial property of sodium citrate.